Listed

Rigel Pharmaceuticals Inc: Form 10-K for the period ended Dec 31, 2020

Filed with the SEC on Mar 2, 2021 and accepted by EDGAR at Mar 2, 2021, 16:05 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-10-01 to 2020-12-31$18.4mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue12 months2020-01-01 to 2020-12-31$108.6mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue12 months2020-01-01 to 2020-12-31$895.0kus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2020-10-01 to 2020-12-31$17.4mus-gaap:GrossProfit
Selling, general and administrative12 months2020-01-01 to 2020-12-31$76.6mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income12 months2020-01-01 to 2020-12-31−$29.0mus-gaap:OperatingIncomeLoss
Interest expense12 months2020-01-01 to 2020-12-31$1.4mus-gaap:InterestExpense
Net income3 months2020-10-01 to 2020-12-31−$19.2mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2020-10-01 to 2020-12-31−$0.11us-gaap:EarningsPerShareBasicAndDiluted
Diluted shares (weighted)3 months2020-10-01 to 2020-12-31169,039,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2020-01-01 to 2020-12-31−$52.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2020-01-01 to 2020-12-31$1.3mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2020-12-31$30.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-12-31$89.0mus-gaap:AssetsCurrent
Total assetsAt period end2020-12-31$110.4mus-gaap:Assets
Current liabilitiesAt period end2020-12-31$40.8mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2020-12-31$20.0mus-gaap:LongTermDebt
Shareholders' equityAt period end2020-12-31$34.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001558370-21-002254. Last ingested by Listed: Nov 14, 2026, 23:09 ET. Listed shows no prices and gives no investment advice.